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Abstract
Background: Pseudomonas aeruginosa is the leading cause of morbidity and mortality in patients
with cystic fibrosis (CF). With chronicity of infection, the organism resides as a biofilm, shows
multi-drug resistance, diversifies its colony morphology and becomes auxotrophic. The patients
have been found to be colonized with multiple genotypes. The present work was carried out to
characterize P. aeruginosa isolated from children with cystic fibrosis using phenotypic and genotypic
methods.
Results: We studied 56 patients with CF attending the Pediatric Chest clinic at All India Institute
of Medical Sciences, New Delhi, India during August 1998-August 2001. These patients were
regularly followed up at the clinic. Out of 56 patients, 27 were culture positive for P. aeruginosa
where 8 were chronically infected (Group1) and 19 were intermittently colonized with the
organism (Group2). Patients under Group1 had significantly higher rates of hospitalization, death
and colonization with different colony morphotypes (p < 0.05). The isolates from Group1 patients
were the positive producers of extended spectrum beta lactamase. A total of 5 auxotrophs were
recovered from 2 patients where one was chronically infected with P. aeruginosa and the other was
a recently enrolled patient. The auxotrophs had the specific requirement for methionine and
arginine. Molecular typing revealed 33 ERIC-PCR (E1-E33) and 5 PCR-ribotyping (P1-P5) patterns.
By ERIC-PCR, 4 patients were colonized with 2–4 genotypes and the remaining 23 patients were
colonized with the single genotype.
Conclusion: With chronicity of infection, P. aeruginosa becomes multidrug resistant, diversifies its
colony morphology, acquires mucoidity and shows auxotrophy for amino acids. The chronically
infected patients can be colonized with multiple genotypes. Thus in a particular clinical set up, high
index of suspicion should be there for diagnosis of CF patients so as to prevent the delay in
diagnosis and management of CF patients.
Published: 21 July 2005
BMC Microbiology 2005, 5:43 doi:10.1186/1471-2180-5-43
Received: 03 April 2005
Accepted: 21 July 2005
This article is available from: http://www.biomedcentral.com/1471-2180/5/43
© 2005 Agarwal et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 11
(page number not for citation purposes)
BMC Microbiology 2005, 5:43 http://www.biomedcentral.com/1471-2180/5/43Background
Cystic fibrosis (CF) is the recessive genetic disorder of
Caucasian race. CF in Asians and Indians was thought to
be almost nonexistent in the past. However, recent reports
have suggested CF to be more common in Indian popula-
tion than previously thought. For proper management, it
is important to diagnose the infection in the patients with
CF [1-3].
The mutations in the cystic fibrosis transmembrane regu-
lator gene in CF patients lead to recurrent and chronic res-
piratory tract infections, which serves as a major cause of
morbidity and mortality [4]. If appropriate antibiotics are
used, the quality of life improves in CF patients. Thus, the
knowledge of the etiological agents and their antimicro-
bial susceptibility can help in planning the appropriate
antibiotic therapy to be instituted in CF patients.
Infection due to Pseudomonas aeruginosa (P. aeruginosa)
has been implicated as a major cause of morbidity and
mortality in patients with CF [5-8]. Once P. aeruginosa col-
onizes the respiratory passages, it is rarely possible to
eradicate it. Prolonged and repeated administration of
drugs lead to the development of multidrug resistance in
P. aeruginosa strains. To detect emergence of the resistant
strains, it is important to monitor the antibiotic suscepti-
bility pattern of P. aeruginosa isolates. Increased resistance
to gentamicin, quinolone and cephalosporins has been
reported in chronically infected patients [9,10].
With severity of pulmonary infection, the organism
undergoes phenotypic modification, which helps in its
persistence under adverse environment of the respiratory
tract. The organism diversifies into different colony mor-
photypes [11,12] and develops antibiotic resistance for its
survival. This may be due to an adaptation of the organ-
ism to the host defense mechanisms and antibiotic selec-
tive pressure [13]. Under recurrent and chronic
endobronchial P. aeruginosa infections, the initial coloni-
zation is with nonmucoid forms of an organism but with
progressive lung tissue damage, it gets converted to the
mucoid form. The mucoidity helps an organism to grow
as biofilm, which serves as a protective niche and helps to
evade the host immune response and action of antibiot-
ics. The organism also becomes auxotrophic for amino
acid due to high amino acid concentration in the respira-
tory passages. The most commonly required amino acid
reported in literature is methionine while other amino
acids-leucine, arginine and ornithine have been required
by a minority of P. aeruginosa strains [14].
During the course of infection, the organism may undergo
genotypic changes. The chronically infected patients have
been found to have long-term colonization by one pre-
dominant genotype but variation in genotypes within a
single patient has also been observed [13,15].
Since no data is available on the characterization of P. aer-
uginosa from CF patients in India, the present study was
undertaken to study phenotypic and genotypic variations
of P. aeruginosa isolated from CF patients attending the
Pediatric Chest Clinic at All India Institute Of Medical Sci-
ences (AIIMS), New Delhi, INDIA.
Results
Subjects
A total of 56 patients with CF regularly attended the Pedi-
atric Chest Clinic between August 1998-August 2001.
These patients were followed monthly at the chest clinic.
At the time of enrollment, all the patients were below 15
yrs of age (mean age (yrs) ± standard deviation was 5.33
± 4.3 and median age was 4.5). The male: female ratio was
2:1.
Out of 56 patients, culture positive infection was observed
in 33(58.9%) patients of whom 27(81.8%) were culture
positive for P. aeruginosa and 6(18.2%) patients were cul-
ture positive for organism other than P. aeruginosa where
one patient each was colonized with Citrobacter freundii,
Staphylococcus aureus, Escherchia coli, Enterobacter sp and
two patients were colonized with Klebsiella pneumoniae.
The rate of infection with P. aeruginosa was significantly
higher than the rate of infection with organism other than
P. aeruginosa in CF patients (p < 0.05). Out of 27 culture
positive patients, 8 had chronic infection with the organ-
ism and were included in Group1. The remaining 19
patients were intermittently colonized with the organism
and were included in Group2.
Table 1: Antibiograms
Antibiogram Susceptibility to 
antibiotics
Total isolates (%)
A1 S to all 102(29.1)
A2 R to Genta only 81(23.1)
A3 R to Genta+Cipro 85(24.3)
A4 R to Cipro only 24(6.9)
A5 R to Genta+Pipra 23(6.6)
A6 R to 
Genta+Cipro+CAZ
24(6.9)
A7 R to Genta+CAZ 5(1.4)
A8 R to 
Genta+Cipro+Pipra
6(1.7)
Genta: Gentamicin; Cipro: Ciprofloxacin; Pipra: Piperacillin; CAZ: 
Ceftazidime CAZ:
S: Sensitive; R: Resistant
+: Indicates "and"Page 2 of 11
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tion and 4 have died. Of the 4 deaths, 3 occurred during
the hospitalization. All the patients who required hospi-
talization were culture positive for P. aeruginosa and were
followed daily. The mean duration of hospitalization was
12 days (range was 7–20 days). Out of 9 patients, 6 were
included in Group1 and 3 in Group 2. All 4 patients who
died, had pulmonary exacerbations and were chronically
infected with P. aeruginosa. The mortality related to P. aer-
uginosa infection in the study was 14.8%. The frequency of
hospitalization and death in chronically infected patients
was significantly higher as compared to intermittently col-
onized patients with P. aeruginosa (p < 0.05).
Antimicrobial susceptibility
Three hundred and fifty P. aeruginosa isolates were recov-
ered from 27 patients where 94(26.9%) showed the
mucoid morphotype (Type5) and the rest 256 (73.1%)
isolates showed nonmucoid morphotype(Type1–4 and
Type 6). The antimicrobial susceptibility was determined
by agar dilution method based on NCCLS guidelines and
antibiograms were further constructed (Table 1). One
hundred and forty three (41%) isolates were multidrug
resistant and showed A3 and A5-A8 antibiogram. All the
isolates were recovered from chronically infected patients.
We further characterized all 29 P. aeruginosa isolates that
showed resistance to ceftazidime and were the positive
producers of extended spectrum beta lactamase (ESBL).
These isolates were detected as ESBL positive by disk dif-
fusion according to NCCLS guidelines (Fig 1A) and fur-
ther confirmation was done by Etest method (Fig. 1B).
Twenty-four of the 29 (82.8%) ESBL positive isolates were
multidrug resistant (A6 antibiogram). All 29 isolates were
found sensitive to imipenam and meropenam.
The ESBL positive isolates were recovered from 3 patients
(PCC.No. 180/95, 160/98 and 499/00) where 2 (PCC.No.
180/95 and 160/98) were chronically infected and one
patient (PCC.No.499/00) was intermittently colonized.
Out of 29 ESBL positive isolates, 27 were recovered from
the patient (PCC.No. 180/95) during his different follow-
ups past two years and 1 isolate each was recovered from
2 patients (PCC.No. 160/98 and 499/00).
Phenotypic characterization of P. aeruginosa isolates
Colony morphotypes
Out of 27 patients infected with P. aeruginosa, 7 harbored
different colony morphotypes in a single sputum sample
while the rest 20 patients harbored Type 1 colony mor-
photype. All the 7 patients were chronically infected with
the organism(Group 1). The rate of colonization with dif-
Detection of Extended spectrum β lactamase in P. aeruginosa isolate from a patient (180/95) byFigure 1
Detection of Extended spectrum β lactamase in P. aeruginosa isolate from a patient (180/95) by:A. Disc Diffu-
sion method (Amika: Amikacin; Cipro: Ciprofloxacin; Pipra: Piperacillin; Genta: Gentamicin; CAZ: Ceftazidime). B. Etest 
method (AB Biodisk, Sweden).
A BPage 3 of 11
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cantly higher in Group 1 patients (p < 0.05).
Six (85.7%) of 7 patients harbored mucoid P. aeruginosa
in their respiratory samples and all were chronically
infected. The rate of colonization with mucoid P. aerugi-
nosa was significantly higher (75%) in chronically
infected patients (p < 0.05). Of the 6 patients who were
positive for mucoid P. aeruginosa, 3 have died.
Out of 350 P. aeruginosa isolates, 194(55.4%) showed
Type 1 morphotype. The distribution of antibiogram
among colony morphotypes is shown in Table 2.
Auxotrophy
Out of 350 P. aeruginosa isolates, 5 were auxotrophs,
which did not grow on minimal agar medium (MAM) and
required Mueller Hinton agar (MHA) for their growth. Of
the 5 auxotrophs, four (isolate No.2–5) were isolated
from the chronically infected patient (PCC.No.180/95)
who was diagnosed as CF six years ago. One auxotroph
(isolate No.1) was isolated from a recently enrolled
patient (PCC.No.499/00). The respiratory samples col-
lected during their subsequent follow-ups were found
negative for the presence of auxotrophs. These auxotrophs
were recovered when these patients presented with pul-
monary exacerbation.
The detection of specific amino acid requirements of aux-
otrophs revealed that 3(isolate No.1–3) had the specific
requirement for arginine (Fig. 2) and 2(isolate No. 4,5)
for methionine. The reproducible results were obtained
on repeating the experiment thrice.
The resistance against different antibiotics was compared
between auxotrophs and prototrophs. Although auxo-
trophs were small in number, they showed significantly
higher resistance against ceftazidime (60%) as compared
to prototrophs (p < 0.05). Three auxotrsophs (isolate No.
1–3) were multidrug resistant (A6 antibiogram) and the
producers of ESBL. The reproducible results were obtained
on repeating the experiment thrice.
Molecular characterization of P. aeruginosa isolates
Molecular characterization of P. aeruginosa isolates (N =
350) recovered from 27 patients infected with P. aerugi-
nosa was achieved by Enterobacterial Repetitive Intergenic
Consensus Polymerase Chain Reaction (ERIC-PCR) and
PCR-ribotyping.




Total Number of isolate (%) showing respective Antibiograms
A1 A2 A3 A4 A5 A6 A7 A8
Type 1 (194) 102 (52.5) 23 (11.8) 27 (10.3) 4 (1.5) 15 (7.7) 14 (7.2) 3 (1.5) 6(3)
Type2 (26) 5 (19.2) 0 10(38.5) 2(7.7) 1(3.8) 7(27) 1(3.8) 0
Type3 (23) 9 (39.1) 0 6(26.1) 5(21.7) 0 3(13.0) 0 0
Type4 (5) 2 (40) 0 2 (40) 1(20) 0 0 0 0
Type5 (94) 0 39 (41.5) 48 (51.1) 0 7(7.4) 0 0 0
Type6 (8) 0 5 (62.5) 1 (12.5) 0 0 1(12.5) 0 1(12.5)
N = Total Number of isolates
Detection of Auxotrophy of P. aeruginosa. Isolate No: Patient PCC.NFigure 2
Detection of Auxotrophy of P. aeruginosa. Isolate No: 
Patient PCC.No. 1: PCC.No. 499/2000; 2–5: PCC.No. 
180/95, A: P. aeruginosa ATCC 27853; N: P. aeruginosa 
NCTC 50184(meth-). Plate A: Growth of P. aeruginosa on 
MAM supplemented with arginine only, Plate B: Growth of 
P. aeruginosa on MAM supplemented with all 22 amino 
acids Plate C: Growth of P. aeruginosa on MAM supple-
mented with all 22 amino acids except arginine,Page 4 of 11
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A total of 33 ERIC-PCR (E1-E33) patterns were con-
structed (Table 3). All 27 patients infected with P. aerugi-
nosa harbored different genotypes with their unique ERIC-
PCR pattern except one patient (PCC.No. 499/00) who
was colonized with the similar genotype (E1). Out of 8
patients who were chronically infected with P. aeruginosa,
4 patients (PCC.No.180/95, 179/93, 160/98 and 10/99)
were colonized with 2–4 genotypes (Fig. 3A&3B). The
remaining 23 patients (Group1 = 4 and Group 2 = 19
patients) were colonized with a single genotype.
PCR-ribotyping
A total of 5 PCR ribotyping patterns (P1-P5) were
obtained (Fig. 4A &4B). The molecular weight (bp) of
each PCR-ribotyping pattern was P1:570, P2: 730, P3:
1500 &610, P4: 600 and P5: 570&130. Twenty four of 27
patients harbored P. aeruginosa with a single PCR-ribotyp-
ing Pattern P1 and 3 patients (PCC.No. 180/95, 160/98
and 179/93) were colonized with P. aeruginosa with 2 or
more PCR-ribotyping patterns. All 3 patients were chron-
ically infected with the organism. Isolates from patient
PCC.No 180/95 Pattern P1-P4, PCC.No. 160/98 Pattern
P1 and P2 and patient PCC.No. 179/93 Pattern P1 and
P5.
By ERIC-PCR, P. aeruginosa isolates from 26/27 patients
revealed different genotypes (E1-E33) while by PCR-
ribotyping, 24/27 patients revealed a single PCR-ribotyp-
ing pattern (Pattern P1).
Table 3 shows the compilation of results on the patient
basis including the phenotypic and genotypic characteris-
tics of each patient.
Discussion
Cystic fibrosis (CF) is the most common inherited fatal
disease in Caucasian population. This generalized disor-
Table 3: Phenotypic and genotypic characteristics of P. aeruginosa isolated from cystic fibrosis patients (Total No. of patients infected 
with P. aeruginosa = 27)
S.No. PCC.No. Total isolates Phenotypic features Genotypic pattern
Colony morphotype Antibiogram ESBL Auxotrophy ERIC-PCR PCR-ribotyping
Group1
1 180/95 146 Type 1–6 A1-A4, A6-A8 + + E1-E4 P1-P4
2 179/93 59 Type 1,2,5 A1-A5, A7 - - E5-E7 P1, P5
3 174/97 22 Type 1 A1 - - E8 P1
4 308/98 22 Type1–3, 5 A1, A2, A5 - - E9 P1
5 10/99 22 Type1, 3 A1, A2, A4, A5 - - E10, E11 P1
6 160/98 19 Type1, 3,5 A3-A5, A7, A8 + - E12, E13 P1, P2
7 121/99 19 Type1–3, 5 A1, A2 - - E14 P1
8 308/00 4 Type 2,3,5 A1, A4 - - E15 P1
Group2
9 167/98 4 Type1 A1 - - E16 P1
10 250/99 4 Type1 A1 - - E17 P1
11 5/00 4 Type1 A1 - - E18 P1
12 256/99 3 Type1 A1, A2 - - E19 P1
13 337/98 3 Type1 A1 - - E20 P1
14 38/95 2 Type1 A1 - - E21 P1
15 202/98 2 Type1 A1, A3 - - E22 P1
16 312/99 2 Type1 A1 - - E23 P1
17 170/99 2 Type1 A1 - - E24 P1
18 499/00 2 Type1 A6 + + E1 P1
19 302/96 1 Type1 A1 - - E25 P1
20 95/96 1 Type1 A1 - - E26 P1
21 82/96 1 Type1 A1 - - E27 P1
22 8/97 1 Type1 A1 - - E28 P1
23 203/99 1 Type1 A1 - - E29 P1
24 133/99 1 Type1 A1 - - E30 P1
25 124/00 1 Type1 A1 - - E31 P1
26 452/00 1 Type1 A1 - - E32 P1
27 76/01 1 Type1 A1 - - E33 P1
Genta: Gentamicin; Cipro: Ciprofloxacin; Pipra: Piperacillin; CAZ: Ceftazidime CAZ: S: Sensitive; R: Resistant +: Indicates "and"Page 5 of 11
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by mutations in cystic fibrosis transmembrane regulator
gene in the airway epithelial cells and submucosal glands.
These patients are very prone to bronchopulmonary infec-
tion due to lack of the innate defensive mechanisms. Pul-
monary infection is the most common cause of morbidity
and mortality in CF patients [16].
CF was thought to be extremely rare in India. However,
recent reports from Indian subcontinent suggested CF to
be more common in Indian population than what was
previously thought [1]. In our study, we have followed all
56 patients attending the Pediatric Chest Clinic at All
India Institute Of Medical Sciences, New Delhi, INDIA
between August 1998-August 2001. The median age of
diagnosis of patients was 4.5 years, which was much
higher than what was earlier reported in the literature
where the median age was found as 6 and 12 months
among Caucasian American and Indian American chil-
dren respectively [17]. This may be due to delayed diagno-
sis of CF patients in India.
P. aeruginosa has been the predominant bacterium associ-
ated with pulmonary infection in patients with CF [18-
22]. In our study, P. aeruginosa was also found as an impli-
cated organism in 82% culture positive patients and its
rate of infection was significantly higher as compared to
the other organisms in CF patients. The colonization with
P. aeruginosa has been linked with pulmonary
deterioration of CF patient resulting in an increased risk of
hospitalization [21]. In the study, all the patients (n = 9)
who required hospitalization were chronically infected
with P. aeruginosa.
Besides morbidity, P. aeruginosa has been associated with
increased mortality [18-22]. In the study all the 4 patients
who died were chronically infected with P. aeruginosa.
Thus significant higher rates of hospitalization and death
were observed among patients chronically infected with P.
aeruginosa.
Although prolonged and frequent administration of anti-
biotics has been useful in the treatment of pulmonary
exacerbations, there is risk of development of multiple
drug resistance in P. aeruginosa strains. In the study, 41%
isolates were multidrug resistant and were recovered from
chronically infected patients, indicating the possible role
of antibiotic pressure. Similar findings have been reported
elsewhere [23-25].
All three patients infected with ESBL positive isolates were
found sensitive to meropenam and imipenam. The simi-
ERIC-PCR patterns of P. aeruginosa isolates from the patientFigure 3
ERIC-PCR patterns of P. aeruginosa isolates from the patient A. PCC. No. 180/95. • Lane M : 100 bp ladder, • 
Lane 1 : Pattern E1, • Lane 2 : Pattern E3, • Lane 3–5 : Pattern E1, • Lane 6–11 : Pattern E2. B. PCC.No. 180/95 and 
179/93 • Lane M : 100 bp ladder, • Lane 1–7 (PCC.No.180/95) : Pattern E4, • Lane 8 (PCC. No. 179/93) : Pattern E5, 
• Lane 9 (PCC.No.180/95) : Pattern E4, • Lane 10 : P. aeruginosa ATCC 27853 • Lane 11 : Negative control
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PCR-ribotyping of P. aeruginosa isolates from the patient A. PCC.No. 180/95 • Lane M : 100 bp ladder, • Lane1, 3, 7 
and 9 : Pattern P1, • Lane 2, 4 and 8 : Pattern P2, • Lane 5, 10–14 : Pattern P3, • Lane 6 : Pattern P4B. PCC.No. 180/95 
and 179/93 • Lane M : 100 bp ladder, • Lane 1,3 and10 (PCC.No.180/95) : Pattern P2, • Lane 2,4 (PCC.No.180/95) : 
Pattern P4, • Lane 5–7 and 9 (PCC.No.180/95) : Pattern P1, • Lane 8 (PCC.No.179/93 : Pattern P5, • Lane 11 : Neg-
ative control
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have been found the most effective and reliable against
ESBL positive isolates [26].
During chronic infection with the organism, there is pro-
gressive anatomical deterioration of the CF lung, which
provides a highly spatial structured environment leading
to diversification of the organism into six different colony
morphological types-Type1-Type 6[12]. This
diversification enhances the capacity of an organism to
survive in lower respiratory tract of CF patients [13]. In the
present study, 7/8(87.5%) chronically infected patients
harbored different colony morphological types in the spu-
tum samples.
Once P. aeruginosa has colonized the respiratory passages
of CF patients, it leads to the induction of mucoidity,
resulting in persistent infections. In the study, 6/8(75%)
patients who were chronically infected with P. aeruginosa
harbored mucoid P. aeruginosa in their respiratory sam-
ples. Our finding in agreement with the earlier reports
where an increased association of mucoidity with chronic-
ity of infection was observed [4,27,28]. Out of 4 patients
who died, 3(75%) harbored mucoid colonies in their res-
piratory samples signifying the association of mucoidy
with high mortality in CF patients. Our finding was in
accordance with the earlier study where association of
mucoidity with high risk of death was observed [26].
The antimicrobial susceptibility among mucoid and non-
mucoid isolates was compared. The mucoid isolates
showed increased resistance against gentamicin and lower
resistance against beta lactam (7.4% to piperacillin and
no resistance to ceftazidime). The results were analogy to
the studies where high resistance to aminoglycosides
[29,30] and low resistance to beta lactam [31,32] was
observed among mucoid isolates.
With chronicity of infection, there is an increase in con-
centration of amino acids in bronchial secretions, which
is due to active epithelial transport, plasma exudation and
protease activity in lung tissue and surface fluid. This
results in development of auxotrophy for certain amino
acids required for growth. In the present study, auxo-
trophic P. aeruginosa was found in 2/27(7.4%) patients in
contrary to an earlier report where auxotrophy of P. aeru-
ginosa was found in 86% patients infected with the organ-
ism [33]. The reason for low percentage of auxotrophs
among our patients may be due to lower number of
chronic patients in this study.
Furthermore in the study, 3/5 auxotrophs had arginine
requirement and the remaining 2 were auxotrophic for
methionine. This was in agreement with the earlier reports
where methionine and arginine were considered as the
most commonly required amino acids by auxotrophs
[14,33,34]. As these strains could be more resistant to
antibiotics, it is important to study auxotrophy of isolates
in CF patients with severe P. aeruginosa infection in order
to plan out appropriate therapy for the management of CF
patients.
Bacterial typing schemes are based on phenotypic or gen-
otypic analysis of multiple isolates within a particular spe-
cies. Such analysis helps in investigation of outbreaks and
determines the recurrence or relapse of an infection. The
epidemiology of P. aeruginosa infection in CF patients has
been hampered since the conventional phenotyping
methods-phage and pyocin typing have poor discrimina-
tory power and poor reproducibility respectively. Genetic
typing methods have shown to be more discriminatory
than phenotypic methods for typing P. aeruginosa CF
isolates [35]. Various genotypic typing methods- restric-
tion fragment length polymorphism (RFLP) analysis of tox
A I and pil A loci, pulse field gel electrophoresis (PFGE),
random amplified DNA polymorphism (RAPD) PCR
have been used to identify the number of strains coloniz-
ing the CF patient [13].
PCR-ribotyping is based on the uniform spacer region in
rRNA operons of P. aeruginosa [36] resulting in low degree
of heterogeneity of rRNA operons. In the study, majority
of isolates showed the single PCR-ribotyping Pattern P1,
probably due to the above reason. Hence for the study of
dynamic of P. aeruginosa strain variation, ERIC-PCR may
be a useful tool.
By ERIC-PCR, all 27 culture positive patients except one
were found colonized with the unique genotype (E1-
E33). This indicates that cross-colonization among unre-
lated CF patients was uncommon. The results were
concordant to the earlier studies where cross-infection
between unrelated patients was considered unusual
[37,38]. All 27 patients except 4 were colonized with the
single persistent genotype. These 4 patients were chroni-
cally infected and were colonized with 2 or more geno-
types. Our results were in agreement with the previous
studies where majority of CF patients were colonized with
a predominant genotype for longer period of time but
high degree of genotypic variability within patients have
been observed suggesting that the colonizing strain may
occasionally be replaced [13,39-41].
Thus we have found that CF is a problem in our country
but delayed diagnosis and low index of suspicion have
delayed the appropriate management of these patients.
Although all the patients attending the Pediatric chest
clinic were included in the study, the number of patients,
especially the chronic ones, was limited in India, which
further limited the number of chronic patients. AlthoughPage 8 of 11
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to answer all the epidemiological questions, these results
indicate that a larger scale CF study should be conducted
in India.
Conclusion
P. aeruginosa is the major colonizer of the respiratory pas-
sages of CF patients. The patients with chronic infection
showed significantly higher rates of hospitalization and
death. With chronicity of infection, the organism under-
goes phenotypic and genotypic variations. Among pheno-
typic variations, the organism becomes multidrug
resistant, diversifies its colony morphology, acquires
mucoidity and becomes auxotrophic for various amino
acids. The multiple genotypes have been found to colo-
nize the respiratory passages of CF patients.
Thus in a particular clinical set up, high index of suspicion
should be there for diagnosis of CF patients so as to pre-
vent the delay in diagnosis and management of CF
patients. The routine microbiological examination of res-
piratory samples from CF patients are advised to study the
characteristics of the infecting agents of which P. aerugi-
nosa is the most common.
Methods
Subjects
All patients with CF (age equal to or less than 15 years)
attending the Pediatric Chest Clinic at All India Institute
Of Medical Sciences between August 1998-August 2001
were included in the study. There was a regular monthly
follow-up of each patient to the clinic. Patients who
required hospitalization were admitted to the Pediatric
ward and were followed daily. The diagnosis of CF was
based on both clinical and laboratory parameters [42].
For analysis, patients were divided into 2 groups -Group 1
and Group 2 based on the chronicity of infection with P.
aeruginosa [12]. Patients under Group 1 were chronically
infected with P. aeruginosa for the past two years and
Group 2 included patients who were intermittently colo-
nized with the organism.
Sample collection
During each visit of a patient to the clinic and during the
period of hospitalization, a representative sample – spu-
tum and/or throat swab after physiotherapy was collected
[41]. The sputum sample was collected directly in a sterile
vial after coughing. Throat swab was considered as an
alternative respiratory sample and was collected from
children who were either below 2 years of age or were not
able to expectorate sputum [43].
Isolation and characterization of P. aeruginosa strains
The sputum was vortexed (for complete homogenization)
and cultured on Chocolate agar, Blood agar containing
5% sheep blood and Mac Conkey agar (Hi Media, Mum-
bai). The plates were incubated at 37°C for 18 hrs. P. aer-
uginosa was identified by standard bacteriological




The single representative from each colony morphotype
was taken and tested for antimicrobial susceptibility by
agar dilution method as per NCCLS guidelines [45]. Of
the six colony morphotypes, Type 5 was the mucoid mor-
photype and the rest morphotypes(Type 1–4 and Type 6)
were the nonmucoid morphotypes. Depending on
antimicrobial susceptibility of an organism, antibiograms
were constructed where intermediate and resistant catego-
ries were clubbed. The antibiotics tested were gentamicin,
ciprofloxacin, piperacillin and ceftazidime. All these anti-
biotics were procured from Hi Media, Mumbai. P.
aeruginosa ATCC 27853 and Escherchia coli ATCC
25922(ATCC, USA) served as the control strains. Those
isolates, which showed resistance to two or more than two
antibiotics were considered multidrug resistant [10].
Production of Extended spectrum beta lactamase (ESBL)
Those isolates, which showed resistance to ceftazidime
(CAZ) were tested for ESBL production by Disc Diffusion
according to NCCLS guidelines [46] and by Etest method
(AB BIODISK, Sweden). All ESBL positive isolates were
further tested for carbapenam-imipenam and carbap-
enam susceptibilty by disk diffusion method [46].
Phenotypic characterization of P. aeruginosa isolates
Different phenotypic features of P. aeruginosa were studied
in CF patients. The phenotypic features included colony
morphotypes and auxotrophy.
Colony morphotypes
Based on colony morphology of the organism, there are
six different colony morphotypes of P. aeruginosa [12].
The presence of six different morphotypes was observed in
respiratory samples of CF patients. Type 5 morphotype
showed mucoidy, which is one of the virulence factor of
the organism.
Auxotrophy
All P. aeruginosa isolates from CF patients were tested for
auxotrophy. The inoculum was adjusted to 0.5 Mc Farland
and diluted to have the final concentration of 104cells/µl.
One microlitre of the inoculum was spotted on Mueller
Hinton agar (MHA) and Minimal agar medium (MAM)
where MHA served as the complex medium and MAM as
nutrient deficient medium. The plates were incubated at
37°C for 48 hrs. Those isolates, which did not grow on
MAM plate but grew on MHA were considered auxo-Page 9 of 11
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MHA and MAM plates were considered prototrophs. P.
aeruginosa NCTC 50184 (meth -) and P. aeruginosa ATCC
27853 were included as the known auxotrophic and pro-
totrophic strain respectively. The specific amino acid
requirements were identified.
Identification of specific amino acid requirements
The stock solution of all 23 L-amino acids including
cysteine, proline, lysine, arginine (Sigma, USA), cystine,
methionine, serine (CDH), glutamine, glutamic acid, gly-
cine, histidine, hydroxy-proline, isoleucine, leucine, orni-
thine, phenylalanine, alanine, asparagine, aspartic acid,
threonine, tryptophan, tyrosine and valine (HiMedia,
Mumbai) were prepared at the concentration of 2 mg/ml
in either sterile distilled water or the appropriate solvent.
All the amino acids were filter sterilized by 0.45 µm Mill-
ipore filter (Millipore, USA). The specific amino acid/
acids requirement was determined by two methods [34].
The first method helps in detection of single or multiple
amino acids. In this method, a single amino acid at the
concentration of 20 µg/ml was added to each MAM plate.
The plates were inoculated and incubated at 37°C for 48
hrs. The growth on specific amino acid containing plates
indicated the requirement for single/multiple amino acids
while no growth in any of the MAM plate supplemented
with amino acid indicated either the requirement for two
or more amino acids in combination or some other
growth factor.
The second method helps in detection of combination of
amino acids. All amino acids (at the concentration of 20
µg/ml) less one were added to molten MAM. The plates
were inoculated and incubated as described above. The
specific requirement for an amino acid/combination of
amino acids was evident, if the isolate failed to grow on
agar not containing that particular amino acid.
Antibiotic resistance
The antibiotic susceptibility of auxotrophs and pro-
totrophs was determined by agar dilution method and the
antibiotic resistance was compared between them. The
antibiotics tested were gentamicin, ciprofloxacin, pipera-
cillin and ceftazidime.
Molecular characterization of P. aeruginosa isolates
Molecular typing of P. aeruginosa isolates from all culture
positive patients was done by ERIC-PCR and PCR-ribotyp-
ing. Both the molecular methods were carried out as
described earlier [12].
Statistical analysis
To see the association between the categorical variables,
Chi square test (with Yates correction)/Fischer's exact test
was used. The result was considered significant at 5% level
of significance (p < 0.05). SAS 8.0 statistical package was
used for analysis.
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